Literature DB >> 19491910

Connective tissue diseases: The conundrum of B cell depletion in SLE.

Iñaki Sanz.   

Abstract

Two consecutive trials of rituximab, a B-cell-depleting anti-CD20 monoclonal antibody, have threatened the future of B-cell-targeted therapy for systemic lupus erythematosus (SLE). While rumors of the demise of this approach might be greatly exaggerated, the outcomes of these studies should force academics and the pharmaceutical industry back to the drawing board.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19491910     DOI： 10.1038/nrrheum.2009.100

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  8 in total

1.  New therapies in systemic lupus erythematosus - trials, troubles and tribulations.... working towards a solution.

Authors:  D Isenberg; C Gordon; J Merrill; M Urowitz
Journal:  Lupus       Date:  2008-11       Impact factor: 2.911

2.  New therapies in systemic lupus erythematosus--trials, troubles and tribulations--working towards a solution: part 2--the politically incorrect version.

Authors:  D J Wallace
Journal:  Lupus       Date:  2009-02       Impact factor: 2.911

Review 3.  Update on the treatment of lupus nephritis.

Authors:  M Waldman; G B Appel
Journal:  Kidney Int       Date:  2006-08-23       Impact factor: 10.612

4.  Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy.

Authors:  Jennifer H Anolik; Jennifer Barnard; Teresa Owen; Bo Zheng; Sunil Kemshetti; R John Looney; Iñaki Sanz
Journal:  Arthritis Rheum       Date:  2007-09

Review 5.  B cells and immunological tolerance.

Authors:  Nataly Manjarrez-Orduño; Tâm D Quách; Iñaki Sanz
Journal:  J Invest Dermatol       Date:  2009-02       Impact factor: 8.551

Review 6.  Correlation of circulating CD27high plasma cells and disease activity in systemic lupus erythematosus.

Authors:  T Dörner; P E Lipsky
Journal:  Lupus       Date:  2004       Impact factor: 2.911

7.  Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome.

Authors:  Catherine Melander; Marion Sallée; Pierre Trolliet; Sophie Candon; Xavier Belenfant; Eric Daugas; Phillipe Rémy; Virginie Zarrouk; Evangéline Pillebout; Christian Jacquot; Jean-Jacques Boffa; Alexandre Karras; Virginie Masse; Philippe Lesavre; Caroline Elie; Isabelle Brocheriou; Bertrand Knebelmann; Laure-Hélène Noël; Fadi Fakhouri
Journal:  Clin J Am Soc Nephrol       Date:  2009-03-04       Impact factor: 8.237

8.  Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis.

Authors:  Shouvik Dass; Andy C Rawstron; Edward M Vital; Karen Henshaw; Dennis McGonagle; Paul Emery
Journal:  Arthritis Rheum       Date:  2008-10
  8 in total
  8 in total

Review 1.  Regulatory B cells in autoimmunity: developments and controversies.

Authors:  Claudia Mauri; Paul A Blair
Journal:  Nat Rev Rheumatol       Date:  2010-09-21       Impact factor: 20.543

2.  Indications of rituximab in autoimmune diseases.

Authors:  Iñaki Sanz
Journal:  Drug Discov Today Ther Strateg       Date:  2009-04-01

Review 3.  B cells as therapeutic targets in SLE.

Authors:  Iñaki Sanz; F Eun-Hyung Lee
Journal:  Nat Rev Rheumatol       Date:  2010-06       Impact factor: 20.543

4.  Overexpression of the Cytokine BAFF and Autoimmunity Risk.

Authors:  Maristella Steri; Valeria Orrù; M Laura Idda; Maristella Pitzalis; Mauro Pala; Ilenia Zara; Carlo Sidore; Valeria Faà; Matteo Floris; Manila Deiana; Isadora Asunis; Eleonora Porcu; Antonella Mulas; Maria G Piras; Monia Lobina; Sandra Lai; Mara Marongiu; Valentina Serra; Michele Marongiu; Gabriella Sole; Fabio Busonero; Andrea Maschio; Roberto Cusano; Gianmauro Cuccuru; Francesca Deidda; Fausto Poddie; Gabriele Farina; Mariano Dei; Francesca Virdis; Stefania Olla; Maria A Satta; Mario Pani; Alessandro Delitala; Eleonora Cocco; Jessica Frau; Giancarlo Coghe; Lorena Lorefice; Giuseppe Fenu; Paola Ferrigno; Maria Ban; Nadia Barizzone; Maurizio Leone; Franca R Guerini; Matteo Piga; Davide Firinu; Ingrid Kockum; Izaura Lima Bomfim; Tomas Olsson; Lars Alfredsson; Ana Suarez; Patricia E Carreira; Maria J Castillo-Palma; Joseph H Marcus; Mauro Congia; Andrea Angius; Maurizio Melis; Antonio Gonzalez; Marta E Alarcón Riquelme; Berta M da Silva; Maurizio Marchini; Maria G Danieli; Stefano Del Giacco; Alessandro Mathieu; Antonello Pani; Stephen B Montgomery; Giulio Rosati; Jan Hillert; Stephen Sawcer; Sandra D'Alfonso; John A Todd; John Novembre; Gonçalo R Abecasis; Michael B Whalen; Maria G Marrosu; Alessandra Meloni; Serena Sanna; Myriam Gorospe; David Schlessinger; Edoardo Fiorillo; Magdalena Zoledziewska; Francesco Cucca
Journal:  N Engl J Med       Date:  2017-04-27       Impact factor: 91.245

Review 5.  B-cell-depleting therapy in systemic lupus erythematosus.

Authors:  Manuel Ramos-Casals; Iñaki Sanz; Xavier Bosch; John H Stone; Munther A Khamashta
Journal:  Am J Med       Date:  2012-04       Impact factor: 4.965

Review 6.  B-cell-depletion therapy in SLE--what are the current prospects for its acceptance?

Authors:  Catarina Favas; David A Isenberg
Journal:  Nat Rev Rheumatol       Date:  2009-12       Impact factor: 20.543

Review 7.  The Role of B Cells in Adult and Paediatric Liver Injury.

Authors:  Arzoo M Patel; Yuxin S Liu; Scott P Davies; Rachel M Brown; Deirdre A Kelly; Dagmar Scheel-Toellner; Gary M Reynolds; Zania Stamataki
Journal:  Front Immunol       Date:  2021-09-23       Impact factor: 8.786

8.  Adenosine receptor 2a agonists target mouse CD11c+T-bet+ B cells in infection and autoimmunity.

Authors:  Russell C Levack; Krista L Newell; Berenice Cabrera-Martinez; Justin Cox; Andras Perl; Sheldon I Bastacky; Gary M Winslow
Journal:  Nat Commun       Date:  2022-01-21       Impact factor: 17.694
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.